A clinical trial of SAR 442999
Latest Information Update: 10 Feb 2022
At a glance
- Drugs SAR 442999 (Primary)
- Indications Inflammation
- Focus Adverse reactions
Most Recent Events
- 10 Feb 2022 New trial record
- 04 Feb 2022 According to a Sanofi media release first patient has been enrolled in the trial.